Nektar combines a differentiated immunology platform with improving financial discipline. Operating losses and cash burn have been reduced significantly, R&D is more targeted, and the balance sheet—while smaller—is relatively clean of complex debt and intangible items. The company’s technology base, regulatory designations for its lead asset, and experience in polymer conjugation give it a credible foundation for partnership and future drug development.

At the same time, the company carries notable risks. It remains deeply unprofitable, with persistent negative cash flow and a much‑reduced liquidity buffer, raising the likelihood of future capital needs. Shareholder equity and total assets have contracted sharply, leverage metrics have worsened, and the firm operates in disease areas with strong, entrenched competitors. Clinical, regulatory, and execution risks around rezpegaldesleukin and the early pipeline are high, and any setback could quickly translate into financial strain.

Looking ahead, Nektar’s trajectory will be driven far more by clinical and partnering outcomes than by incremental financial optimization. If upcoming data for rezpegaldesleukin are positive and the company can secure strong development or commercialization partners, it could leverage its platform into a more sustainable business model. If results are mixed or capital remains difficult to obtain, the combination of ongoing cash burn and a weakened balance sheet could constrain strategic options. Overall, the outlook is highly dependent on a few key scientific and strategic milestones, with a wide range of potential scenarios typical for small, clinical‑stage biotech firms.